回复温伟·宋致编辑的信，内容涉及魏申·谭、伊恩·M·麦克尔里、法昆多·达瓦罗等人的《序贯膀胱内吉西他滨和多西他赛是卡介苗治疗中危非肌层浸润性膀胱癌的替代方案》。《欧洲泌尿外科肿瘤学》即将发表。https://doi.org/10.1016/j.euo.2023.06.011 。 - Suppr

Suppr

超能文献

Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.06.011.

作者信息

Tan Wei Shen, O'Donnell Michael, Li Roger, Kamat Ashish M, Packiam Vignesh T

机构信息

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Urology, University of Iowa, Iowa City, IA, USA.

出版信息

Eur Urol Oncol. 2023 Oct 26. doi: 10.1016/j.euo.2023.10.009.

DOI:10.1016/j.euo.2023.10.009

PMID:39492318

Abstract

摘要

相似文献

Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.06.011.回复温伟·宋致编辑的信，内容涉及魏申·谭、伊恩·M·麦克尔里、法昆多·达瓦罗等人的《序贯膀胱内吉西他滨和多西他赛是卡介苗治疗中危非肌层浸润性膀胱癌的替代方案》。《欧洲泌尿外科肿瘤学》即将发表。https://doi.org/10.1016/j.euo.2023.06.011 。

Eur Urol Oncol. 2023 Oct 26. doi: 10.1016/j.euo.2023.10.009.

Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534.回复：沈伟、伊恩·M·麦克尔里、法昆多·达瓦罗等人。序贯膀胱内注射吉西他滨和多西他赛是卡介苗治疗中危非肌层浸润性膀胱癌的替代方案。《欧洲泌尿外科肿瘤学杂志》。2023年；6：531 - 534。

Eur Urol Oncol. 2024 Feb;7(1):163. doi: 10.1016/j.euo.2023.08.007. Epub 2023 Sep 9.

Reply to Christopher Guske, Seyed Behzad Jazayeri, and Roger Li's Letter to the Editor re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027.回复克里斯托弗·古斯克、赛义德·贝赫扎德·贾扎耶里和罗杰·李致编辑的信：关于阿曼达·A·迈尔斯、魏申·谭、瓦伦蒂娜·格拉贾莱斯等人的文章《挑战“卡介苗无反应性”膀胱癌范式：额外的卡介苗是否有效果？》。《欧洲泌尿外科杂志》即将发表。https://doi.org/10.1016/j.eururo.2024.05.027

Eur Urol. 2024 Dec;86(6):e157. doi: 10.1016/j.eururo.2024.10.001. Epub 2024 Oct 16.

Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复法比奥·坎波多尼科、弗朗西斯卡·马蒂奥利和卡洛·因托里尼致编辑的信，信的内容涉及：魏申·谭、亚伦·彭德加斯特、夏洛特·阿克曼等人。中危非肌层浸润性膀胱癌患者的膀胱内热化疗与单纯化疗对比研究（HIVEC-II）：一项2期开放标签随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003 。

Eur Urol. 2023 Jan;83(1):e29-e30. doi: 10.1016/j.eururo.2022.10.009. Epub 2022 Oct 20.

Re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027.回复：阿曼达·A·迈尔斯、沈伟谭、瓦伦蒂娜·格拉贾莱斯等。挑战“卡介苗无反应性”膀胱癌的范式：额外的卡介苗有效果吗？《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2024.05.027

Eur Urol. 2025 Mar;87(3):e54-e55. doi: 10.1016/j.eururo.2024.09.034. Epub 2024 Oct 15.

Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复苏曼·萨胡、阿比谢克·潘迪、斯瓦伦杜·曼达尔、马诺伊·库马尔·达斯和普拉萨特·纳亚克致编辑的信，信的内容涉及魏申·谭、亚伦·彭德加斯特、夏洛特·阿克曼等人的《中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的对比（HIVEC-II）：一项2期、开放标签、随机对照试验》。《欧洲泌尿外科杂志》待发表。https://doi.org/10.1016/j.eururo.2022.08.003 。

Eur Urol. 2023 Feb;83(2):e48-e49. doi: 10.1016/j.eururo.2022.11.006. Epub 2022 Nov 28.

Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.对弗朗切斯科·蒙托西、朱塞佩·罗西耶洛和乔治·甘达利亚致编辑的信的回复，信的主题为：罗伯托·孔蒂耶里、帕特里克·J·亨斯利、魏申·谭等人。欧洲泌尿外科协会极高危非肌层浸润性膀胱癌患者接受卡介苗或早期根治性膀胱切除术的肿瘤学结局。《欧洲泌尿外科肿瘤学》。2023年；6：590 - 596。

Eur Urol Oncol. 2024 Apr;7(2):301. doi: 10.1016/j.euo.2023.09.018. Epub 2023 Oct 6.

Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复：沈伟、亚伦·普伦德加斯特、夏洛特·阿克曼等。中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的比较（HIVEC-II）：一项2期、开放标签、随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003

Eur Urol. 2023 Feb;83(2):e47. doi: 10.1016/j.eururo.2022.10.027. Epub 2022 Nov 17.

Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复：沈伟、亚伦·普伦德加斯特、夏洛特·阿克曼等人。中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的比较（HIVEC-II）：一项2期开放标签随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003

Eur Urol. 2023 Feb;83(2):e56-e57. doi: 10.1016/j.eururo.2022.09.035. Epub 2022 Nov 10.

Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.回复：罗伯托·孔蒂耶里、帕特里克·J·亨斯利、魏申·谭等。卡介苗或早期根治性膀胱切除术治疗欧洲泌尿外科学会极高危非肌层浸润性膀胱癌患者的肿瘤学结局。《欧洲泌尿外科肿瘤学》。2023年；6：590 - 596。

Eur Urol Oncol. 2024 Apr;7(2):300. doi: 10.1016/j.euo.2023.09.016. Epub 2023 Oct 12.

引用本文的文献

Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.不同剂量方案诱导并维持顺式膀胱内吉西他滨/多西他赛治疗中高危非肌层浸润性膀胱癌。

World J Urol. 2024 May 11;42(1):315. doi: 10.1007/s00345-024-04992-5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验